Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,218.00",
    "chg": 8.8,
    "chgp": "0.73%",
    "dir": 1,
    "prev_price": "1,209.20",
    "mcapval": "98,832.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "36.06 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Upgraded to Hold as Technicals Improve Amid Mixed Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-3931271",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_mojoScore_3931271.png",
        "date": "2026-04-03 08:12:32",
        "description": "Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial fundamentals despite recent quarterly setbacks. The upgrade, effective from 2 April 2026, highlights a cautiously optimistic outlook amid mixed signals from the pharmaceutical sector."
      },
      {
        "title": "Golden Cross Confirmed: Do Dr Reddys Laboratories Ltd's Other Technical Indicators Agree?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-forms-golden-cross-signalling-potential-bullish-breakout-3931159",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_goldencross_3931159.png",
        "date": "2026-04-02 18:00:28",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Dr Reddys Laboratories Ltd, signalling a golden cross on 2 Apr 2026. Yet, the broader technical landscape presents a nuanced picture, with some indicators supporting the crossover while others suggest caution."
      },
      {
        "title": "P/E at 18.81 vs Industry's 31.34: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downward-pressure-amid-nifty-50-membership-significance-3929777",
        "imagepath": "",
        "date": "2026-04-02 09:21:12",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a member of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only enhances the stock’s visibility among institutional investors but also ensures substantial passive fund flows from index-tracking mutual funds and exchange-traded funds (ETFs). This status typically provides a degree of price support and liquidity, making the stock a focal point for portfolio managers seeking exposure to the Pharmaceuticals & Biotechnology sector.</p>\n                <p>However, the recent price action suggests that even the benefits of index membership cannot fully shield Dr Reddys Laboratories from sector-specific headwinds and valuation ..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-low-amid-price-pressure-3929298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_priceRelatedfactors_3929298.png",
        "date": "2026-04-01 14:31:05",
        "description": "Dr Reddys Laboratories Ltd experienced a notable decline today, touching an intraday low of Rs 1,216.35, reflecting a 3.05% drop from its previous close. The stock underperformed its sector and broader market indices, weighed down by persistent selling pressure and a subdued market environment."
      },
      {
        "title": "P/E at 18.81 vs Industry's 31.39: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3927713",
        "imagepath": "",
        "date": "2026-04-01 09:25:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 18.81, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 31.39. This 40% discount suggests the market is pricing in either lower growth expectations or higher risk relative to peers. Such a valuation gap is notable in a large-cap stock with a market capitalisation exceeding ₹1,06,669 crores. The sector’s elevated P/E reflects optimism about innovation and pipeline prospects, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be viewed more conservatively ..."
      },
      {
        "title": "P/E at 19.28 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amid-mixed-market-performance-3923589",
        "imagepath": "",
        "date": "2026-03-30 09:25:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 19.28, markedly below the sector’s 31.90. This 40% discount suggests the market is pricing in either a more cautious outlook on earnings growth or perceived risks relative to peers. The sector’s elevated P/E reflects optimism around pharmaceutical innovation and robust demand, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys</a> appears to be valued more conservatively. This valuation gap raises the question — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd’s Mixed Week: -1.31% Price Change Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltds-mixed-week--131-price-change-amid-technical-shifts-3921926",
        "imagepath": "",
        "date": "2026-03-28 14:06:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>23 Mar:</strong> Intraday low amid price pressure at Rs.1,252.55 (-3.57%)</p>\n                    <p><strong>24 Mar:</strong> Downgrade to Sell on technical and financial weakness</p>\n                    <p><strong>25 Mar:</strong> Intraday high with 3.29% surge to Rs.1,301.90</p>\n                    <p><strong>27 Mar:</strong> Technical momentum shifts amid mixed signals, closes at Rs.1,281.95 (-1.53%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,298.95</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-mixed-market-signals-3918498",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_technicaldot_3918498.png",
        "date": "2026-03-27 08:02:04",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of late March 2026. Despite a recent upgrade in price action, the stock continues to face mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Surges 3.29% to Day's High of Rs 1303.15 — Outperforms Sector by 1.04 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-329-surge-on-25-mar-2026-3916233",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_priceRelatedfactors_3916233.png",
        "date": "2026-03-25 12:46:07",
        "description": "The Sensex climbed 2.28% on 25 Mar 2026, yet Dr Reddys Laboratories Ltd outpaced both the benchmark and its sector peers with a 3.29% gain, reaching an intraday high of Rs 1303.15. This 1.04 percentage-point outperformance signals a stock-specific strength rather than a mere market tailwind."
      }
    ],
    "total": 515,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
      "datetime": "26-Mar-2026",
      "details": "Allotment of Employee Stock Options",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015",
      "datetime": "24-Mar-2026",
      "details": "Revised Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Mar-2026",
      "details": "Intimation of Board meeting date and Trading Window closure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Upgraded to Hold as Technicals Improve Amid Mixed Financials

2026-04-03 08:12:32

Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial fundamentals despite recent quarterly setbacks. The upgrade, effective from 2 April 2026, highlights a cautiously optimistic outlook amid mixed signals from the pharmaceutical sector.

Read full news article

Golden Cross Confirmed: Do Dr Reddys Laboratories Ltd's Other Technical Indicators Agree?

2026-04-02 18:00:28

The 50-day moving average has crossed above the 200-day moving average for Dr Reddys Laboratories Ltd, signalling a golden cross on 2 Apr 2026. Yet, the broader technical landscape presents a nuanced picture, with some indicators supporting the crossover while others suggest caution.

Read full news article

P/E at 18.81 vs Industry's 31.34: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-02 09:21:12

Significance of Nifty 50 Membership

As a member of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only enhances the stock’s visibility among institutional investors but also ensures substantial passive fund flows from index-tracking mutual funds and exchange-traded funds (ETFs). This status typically provides a degree of price support and liquidity, making the stock a focal point for portfolio managers seeking exposure to the Pharmaceuticals & Biotechnology sector.

However, the recent price action suggests that even the benefits of index membership cannot fully shield Dr Reddys Laboratories from sector-specific headwinds and valuation ...

Read full news article

Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure

2026-04-01 14:31:05

Dr Reddys Laboratories Ltd experienced a notable decline today, touching an intraday low of Rs 1,216.35, reflecting a 3.05% drop from its previous close. The stock underperformed its sector and broader market indices, weighed down by persistent selling pressure and a subdued market environment.

Read full news article

P/E at 18.81 vs Industry's 31.39: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-01 09:25:52

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E of 18.81, markedly below the Pharmaceuticals & Biotechnology industry average of 31.39. This 40% discount suggests the market is pricing in either lower growth expectations or higher risk relative to peers. Such a valuation gap is notable in a large-cap stock with a market capitalisation exceeding ₹1,06,669 crores. The sector’s elevated P/E reflects optimism about innovation and pipeline prospects, but Dr Reddys Laboratories Ltd appears to be viewed more conservatively ...

Read full news article

P/E at 19.28 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd

2026-03-30 09:25:47

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 19.28, markedly below the sector’s 31.90. This 40% discount suggests the market is pricing in either a more cautious outlook on earnings growth or perceived risks relative to peers. The sector’s elevated P/E reflects optimism around pharmaceutical innovation and robust demand, yet Dr Reddys appears to be valued more conservatively. This valuation gap raises the question — Read full news article

Dr Reddys Laboratories Ltd’s Mixed Week: -1.31% Price Change Amid Technical Shifts

2026-03-28 14:06:41

Key Events This Week

23 Mar: Intraday low amid price pressure at Rs.1,252.55 (-3.57%)

24 Mar: Downgrade to Sell on technical and financial weakness

25 Mar: Intraday high with 3.29% surge to Rs.1,301.90

27 Mar: Technical momentum shifts amid mixed signals, closes at Rs.1,281.95 (-1.53%)

Week Open

Rs.1,298.95

Week Close

<...

Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-03-27 08:02:04

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of late March 2026. Despite a recent upgrade in price action, the stock continues to face mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Dr Reddys Laboratories Ltd Surges 3.29% to Day's High of Rs 1303.15 — Outperforms Sector by 1.04 Percentage Points

2026-03-25 12:46:07

The Sensex climbed 2.28% on 25 Mar 2026, yet Dr Reddys Laboratories Ltd outpaced both the benchmark and its sector peers with a 3.29% gain, reaching an intraday high of Rs 1303.15. This 1.04 percentage-point outperformance signals a stock-specific strength rather than a mere market tailwind.

Read full news article

View All News